Department of Pharmacy Practice

College of Pharmacy
masthead

Pharmacy Practice Sponsored Research

Jeffrey Bishop, PharmD

Title:

Schizophrenia Pharmacogenetics cognition and symptom response to antipsychotics
Sponsor:

National Institute of Mental Health
Summary:

The purpose of this study is to investigate the relationship between genetic markers and cognitive and symptom outcomes in patients with schizophrenia who are treated with antipsychotic agents

Julio Duarte, PharmD, PhD

Title:

Development of an NIH Pharmacogenomics Research Network Site
Sponsor:

UIC Vice Chancellor
Summary:

This proposal brings together many of the pharmacogenomics experts on campus to establish the feasibility of assembling a competitive application for Pharmacogenomics Research Network (PGRN) grant. The research team has outlined straightforward objectives to develop a working group of UIC investigators that will identify basic and/or clinical themes for a PGRN application.

Kristen Goliak, PharmD

Title:

Medication Monitoring & Safety in Older Adults (MMSOA): A community-based educational outreach program
Sponsor:

Age Options
Summary:

University of Illinois pharmacy faculty and students provide community based health promotion targeting medication safety and awareness in at-risk seniors in the Chicagoland area. Specifically, the program provides for screening, assessment and evaluation of senior medication drug regimens through one-on-one review and evaluation. In addition, we strive to promote Healthy People 2020 goals and empower senior’s to take control of their health through recommended vaccinations, educational topic discussions, using their medications wisely, making positive health care choices and encouraging effective open communication with their physicians.

Hyun-Young Jeong, PharmD

Title:

Design and Synthesis of Nonpeptide Protease Inhibitors
Sponsor:

Purdue University (NIH)
Summary:

Acquired immunodeficiency syndrome (AIDS) is one of the most destructive epidemics in medical history.  In 2009, the UNAIDS report estimated that 35 million people are living with human immunodeficiency virus (HIV) infection and AIDS, 25 million deaths have occurred, and 14 million children have been orphaned since the epidemic began in 1981.  The discovery of HIV, the etiological agent for AIDS, led to the identification of a number of biochemical targets to combat this devastating disease.  Among them, therapeutic inhibition of a proteolytic enzyme, HIV-1 protease, emerged as a critical drug-development target.  Subsequent design and discovery of protease inhibitors (PIs) and their introduction into the highly active antiretroviral therapy (HAART), marked the beginning of a new era of management of HIV-1 infection and AIDS.  HAART significantly improved the quality of life and life expectancy of patients.  There is no cure for HIV/AIDS and long-term treatment has posed a serious challenge because of the emergence of multidrug-resistant HIV-1 variants.  About 40-50% of those patients who initially achieved favorable viral suppression to undetectable levels experienced treatment failure.  These drug-resistant HIV strains can be transmitted, raising further uncertainty with respect to future treatment options.  In addition, PIs are faced with a number of serious limitations including, major toxicity, tolerance, and adherence to complex medical regimens.  The development of a new generation of PIs effective against drug-resistant HIV and with minimum side effects, are vital to the future management of HIV/AIDS.  Our collaborative research efforts to combat drug resistance led to the development of darunavir, which was first approved for treatment against drug-resistant HIV in June, 2006, and then received full approval for all HIV/AIDS patients including pediatric patients in December, 2008.  While darunavir has become a front line therapy against HIV/AIDS, it is far from ideal as an effective long-term treatment option.  Darunavir is eliminated mainly by hepatic metabolism via cytochrome P450 (CYP)3A4.  For achieve efficacy, darunavir needs to be co-administered with ritonavir, a potent CYP3A4 inhibitor, and this is responsible for multiple drug-drug interactions in patients prescribed with darunavir [1]

Hyun-Young Jeong, PharmD

Title:

Altered Drug Metabolism in Pregnancy
Sponsor:

National Institute of Child Health Development
Summary:

Over 50% of pregnant women take one or more prescription drugs due to pre-existing or newly developing medical conditions. Despite the prevalent use of medications, how pregnancy alters drug disposition is poorly understood. Accurate pharmacokinetic information is crucial for pregnant women because under or over dose may result in detrimental clinical outcomes in both mother and fetus. Clear understanding of altered drug disposition during pregnancy should enable prediction of pharmacokinetic changes of drugs in pregnant women. The aim of this study is to establish effects of estrogen and PRG and CYP expression and drug metabolism in human hepatocytes as well as determine molecular mechanisms by which expression of two major CYP enzymes, CYP3A4 and CYP2D6 is up-regulated during pregnancy

Jeremy Johnson, PharmD


Title:

Prostate Cancer Chemoprevention with Carnosol by dual Disruption of AR/ER
Sponsor:

American Cancer Society
Summary:

Our long-term goal is to understand how diterpenes including carnosol simultaneously disrupt AR and ERα for the prevention of prostate cancer.  Our central hypothesis is that diterpenes are dual AR and ERα disruptors that promote proteolytic degradation of AR and ERα decreasing the proliferative index of prostate cells.  Our hypothesis has been formulated on the basis of our own published data which was the first report of a single chemical entity, carnosol that was able to simultaneously disrupt AR and ERα without agonist properties.  Also, the work of several other groups evaluating diterpenes as either AR or ERα antagonists is supportive of our hypothesis.  We plan to test our central hypothesis and accomplish the objective of this proposal by pursuing the following:  Specific Aim 1.  To characterize the post translational and proteolytic events associated with carnosol induced degradation of AR and ERα in prostate cells. Specific Aim 2.  To determine if carnosol interacting with the ligand binding domain is necessary for proteolytic events associated with carnosol induced degradation of ERα in prostate cells.  Specific Aim 3.  To determine the stage specific chemopreventive efficacy of oral feeding carnosol on prostate cancer initiation and progression using the myc-driven transgenic prostate cancer mouse model. 

Edith Nutescu, PharmD

Title:

Patient-Centered Anticoagulation Self-Monitoring in Minority Patients (K23)
Sponsor:

National Heart, Lung, and Blood Institute
Summary:

Warfarin is the most commonly prescribed oral anticoagulant for the prevention and treatment of thromboem-bolic disorders. The 2 million patients taking warfarin require complex management via frequent laboratory monitoring and dosing adjustments, due to its narrow therapeutic index and considerable intra and inter individual dose-response variability. Poor anticoagulation control during warfarin therapy increases the risk of thromboembolism, major bleeding and death. Approaches recommended to improve quality of anticoagulation include engaging patients to participate in the process of care and maintaining systematic supervision of anticoagulation treatment by providers. The emergence of portable self-testing devices for measuring anticoagulant effect, make it possible for patients on warfarin to engage in their care by self-monitoring the effect of their anticoagulant therapy. Patient self-monitoring has been reported to result in better anticoagulation control when compared to their usual care or monitoring via specialized anticoagulation clinics. Despite favorable results and enhanced patient convenience, the adoption of patient self-monitoring in clinical practice in the US has been limited primarily to non-minority and higher socioeconomic individuals. Factors influencing the adoption of self-monitoring of anticoagulation have not been systematically examined. Understanding these factors is especially important in minority underserved patients who are at highest risk for accessing high quality care. Without this knowledge we will not be able to utilize an effective and convenient self-monitoring technology for patients who are at highest risk for the life-threatening complication. The long term goal is to develop a successful career as a comparative-effectiveness researcher in technology based patient-centered interventions that support convenient, accessible, and cost –effective models of care in high risk patients. The overall objective in this K23 is to identify factors influencing self-monitoring in minority patients and create a tailored self-management education program.

Keith Rodvold, PharmD

Title:

Pharmacokinetics of Ceftaroline in Normal and Obese Subjects
Sponsor:

Forest Research Institute, Inc.
Summary:

The prevalence of obesity is increasing, with the World Health Organization predicting >700 million people will be obese by 2015. “Severe” obesity is increasing at a greater rate than “moderate” obesity. Although obese individuals now account for a significant proportion of the population, there is little guidance on how to adjust drug doses when these individuals require pharmacological intervention. Clinical pharmacokinetic studies should be designed to sufficiently determine dosing metrics for the obese subjects. This investigation has elected to evaluate the current FDA-approved dosage of ceftaroline fosamil 700 mg administered by intravenous infusion

Title:

Impact of Telavancin on Vancomycin Immunoassays that Demonstrated Cross-Reactivity
Sponsor:

Theravance, Inc.
Summary:

The objective of this study is to systematically evaluate the propensity of telavancin and 7-OH-telavancin to result in cross-reactivity in seven commercially available vancomycin systems. This study will confirm or refute the potential cross-reactivity of telavancin and its metabolite, THRX-651540, with commonly used vancomycin assay kits and immunoassay techniques.